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Summary Glioblastoma cells infiltrate brain tissue and migrate preferentially along white matter fibre tracts, an environment that is highly
inhibitory to the migration of astrocytes and the growth of neurites because of the presence of specific inhibitory proteins. In vitro, spreading
and migration of rat C6 glioma cells on a CNS (central nervous system) myelin substrate is correlated with and dependent on the presence of
a metalloprotease. This membrane-bound metalloendoprotease exhibits a blocker profile different from known proteases. Pretreatment of
CNS myelin or of a highly purified CNS myelin component, the inhibitory protein bNI-220, with 06 metalloproteolytic activity converts these
non-permissive substrates into permissive environments for astrocytes and fibroblasts, indicating that this C6 cell-derived metalloprotease
may inactivate myelin-associated inhibitory proteins. Antibodies were raised in chicken against fractions enriched in metalloproteolytic
activity: these antibodies were able to inhibit specifically spreading and migration of C6 glioma cells on a CNS myelin substrate. as well as the
invasion of C6 cells into aduft rat optic nerve explants in vitro. These results suggest a crucial involvement of a membrane-bound
metalloprotease in the mechanisms of C6 glioma migration and infiltration of brain tissue by proteolytic inactivation of the neurite growth
inhibitory proteins present in CNS myelin.
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ProteolI-tic enzymes plax an important role in cancer biologx
(Liotta and Stetler-Stexenson. 1990). The inxolvement of matrix
metalloproteases (Ennis and Matrisian. 1994). plasminogen acti-
xator (Mignatti and Rifkin. 1996) and proteases of the cathepsin
fami1x (Rochefort. 1994) has been shown. especiallx for the
formation of metastases: the breakdow-n of cell-cell contacts and
the extracellular matrix enables the tumour cells to mig-rate
through peripheral tissues and to enter and leax e the blood stream.
Interestingly. the metastases from peripheral tumours. even highly
invasive ones. form onlv circumscribed tumours in the brain and
do not show anv infiltratinc behaxiour within the CNS tissue. In
contrast. hichlx invasix-e CNS tumours rarelv metastasize to
peripheral organs. These obserxations suggest a different mecha-
nism for tumour cell migration within the CNS.
High-grade astrocv-tomas. such as glioblastoma multiforme. are
characterized bv the diffuse infiltration of the surroundinc CNS
tissue (Kleihues et al. 1993). Malignant tumourcells migrate along
blood xessels without intrax-asation (Bemstein et al. 1990: Giese
and Westphal. 1996). but the preferred route forglioma dissemina-
tion is aloncg white matter fibre tracts (Russel and Rubinstein.
1989). CNS white matter. hoxwever. contains inhibitonr proteins
for neurite outgrow-th. axon regeneration and for spreading and
migration of different cell types. including astrocN-tes and fibro-
blasts (Caroni and Schw-ab. 1988: Schwab and Carom'. 1988:
Spillmann et al. 1997).
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Rat C6 glioma. a glial brain tumour cell line induced bv N-nitro-
somethxlurea. shows rapid and diffuse infiltration of brain tissue
in Xivo. Venr similar to human glioblastomas (Benda et al. 1968).
In several in v-itro models wxe showed that C6 glioma cells rapidly
invade optic nerve explants and spread on CNS tissue and purified
CNS mvelin. C6 cell spreading and migration on CNS mxelin can
be blocked by metalloprotease blockers such as o-phenanthroline.
Awhereas blockers for senine. aspartx l and cy steine proteases had no
effect (Paganetti et al. 1988: Amberger et al. 1994). These results
suggest the involvement of a metalloproteolv-tic activitx in the
process ofmigration of C6 gllioma cells on myelin and mvelinated
CNS tissue. A nea-l- designed tetrapeptide. cbz-phe-ala-phe-tyr-
amide. inhibits C6 glioma cell spreading and is degraded with a
slox- time course (AAmberger et al. 1994). A degradation assax
usinc the iodinated tetrapeptide led to the characterization of the
inx ol ed proteolvtic actix ity (AAmberger et al. 1994). A similar
metalloproteolvtic actix-itx was also found in a series ofhigh-grade
human glioma lines and primary tumours (Amberger et al. 1997).
In the present studyxwe report the partial purification ofa metal-
loendoprotease (C6-MPA). expressed in the plasma membrane of
C6 gllioma cells. Fractions highlx enriched in metalloproteolvtic
activitx neutralize the inhibitor- substrate properties of CNS
mvelin and inactixate the neurite grou-th inhibitor- protein bNI-
220 as shoxwn in in xitro cell spreadinc assays. bNI-220 is the
bomine homologue of the neurite growth inhibitorx protein NI-
35/250 previously found in rat CNS myelin (Caroni and Schwab.
1988). Antibodies were raised in chicken against C6-MPA-
containing fractions. The effect of these antibodies was tested in
tissue culture experiments. as wxell as the peptide degradation
assay: in the presence of these antibodies C6 cell spreading, on
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CNS m-elin >-as efficientiv blocked. and cell migration of
glioblastomas >-as significantlv reduced. The amount of C6
glioma cells infiltrating into optic nerve explants w-as also signifi-
cantlx reduced. In a peptide degradation assay. used to exvaluate the
metalloproteolI-tic actix itx expressed bv C6 glioma cells. the anti-
bodies reduced the protease activitv by 40%'.
These results proxvide further indications that a membrane-
bound metalloprotease actixity is involhed in the ability of C6
glioma cells to spread and migrate on CNS mvelin.
MATERIALS AND METHODS
Reagents
Cell culture media wxere from Gibco/BRL (Basle. Sxxitzerland). -
Mlorpholino-ethanesulphonic acid potassium salt (MES). DL-
thiorphan. phenylmethanesulphony-l fluoride (PMSF). leupeptin.
and pepstatin A w ere from Fluka (Buchs. Switzerland). o-
Phenanthroline. CHAPS. sodium dodecyl sulphate SDS). molec-
ular weiaht standards for gel filtration and all other chemicals
wxere purchased from Sigma Chemical Co (St Louis. NIO. USA).
The tetrapeptide carbobenzox\--phe-ala-phe-t\-r-amide >-as s5ynthe-
sized by Bachem (Basle. Sw-itzerland
Cell culture, cell spreading and peptide degradation
assay
NIH/3T3 cells w-ere purchased from the American Type Culture
Collection (MID. USA). Rat C6 rlioma cells w-ere a kind gift from
Dr D Monard (Friedrich Miescher Institute. Basle. Sxxitzerland).
NIH/3T3 fibroblasts and C6 alioma cells wxere arow-n in Dulbecco's
modified Earle's medium (DNIENI) supplemented xith l10%c fetal
calf serum FCS). 100 units ml-' penicillin and 0.5 mg ml strepto-
mvcmn. The cells were harvested by a short trxpsin treatment and
resuspended in DMEMIIOc% FCS (Spillmann et al. 1997).
Substrates w-ere applied to culture dishes (1 cm') )Greiner.
NUrtingen. Germany). incubated oxer night at 4 C and washed
tx-ice wxith Ca--. Msi--free Hanks' balanced salt solution. The
coated >-ells were used immediately for the spreading assay by
adding 10 000 cells cm-'. After I h the cells wxere fixed and quanti-
fied by counting flat. spread cells A-ith processes xs round. attached
cells without processes in four randomlyv chosen areas ofeach ell.
Substrates
CNS myelin
Spinal cord myelin from adult Lewis rats or boxine spinal cord
mvelin w-as purified on a discontinuous sucrose gradient: osmoti-
cally shocked and my elmn proteins wxere extracted Spillmann et al.
1997). The mvelin extract A-as routinely tested for inhibitorV
actixitv of cell spreading x-ith 3T3 fibroblasts. The myelin protein
concentration resulting in 80%;- inhibited fibroblasts w-as used as
substrate for the spreading and migration assax ( 15-20 jg cm-')
bNI-220
Boxine neurite growxth inhibitor .M1 220 kDa )bNI-220) xas puni-
fied according to Spillmann et al (1998) and coated on culture
dishes at protein concentrations of 1 Pg cm- as described aboxe.
Control substrate
CNS mxelin extraction buffer. control fractions or po0x -L-
lvsine/lI% BSA xxere used as control substrate.
Migration assay
The assay was performed according to Berens et al (1994) xxith
some modifications as described by AXmberger et al (1997). The
area occupied by attached cells in each wxell >-as recorded at 2 h.
6 h. 12 h and 24 h in -itro. Each x-alue represents the mean ofthree
wxells and each experiment was repeated three times. 'Where indi-
cated. IgY antibodies (10 50 ug. 100 jig ml xxere added to
the culture medium during the assay ( see belowx.
Optic nerve explant infiltration assay
Optic ner-e explants were prepared as described iSchwab and
Thoenen. 1985. Briefly. the nerxes w-ere rapidly dissected out of
10- to 1l-week-old rats (Lewxis). cleaned from the meninges. X-
irradiated to reduce glial cell proliferation and placed under a
Teflon ring sealed to a culture dish with silicon Lrease. Three
chambers communicating only- b- the explants were obtained in
this xav (Campenot chambers). C6 cells were stained with the
fluorescent dyes Di-I (Sigma) for 30 min and Hoechst for 3 h.
wxashed three times with DMEMIlO%c FCS and 200 000 C6 cells
w-ere placed into the inner chamber and incubated for 14 daxs. The
medium was exchanged exerv day. At the end of the experiment
the optic nerx es w-ere remoxed. flat mounted in tissue tek
(Reichert-Jung. Nussloch. Germany and frozen at -40C. Frozen
sections (15 gm) w-ere serially cut on a crvostat. Labelled infil-
trated cells w-ere counted under a fluorescence microscope
(Olympus Vanox-5) starting from the tip of the nerves where cells
wxere added. The whole nerve >-as divided into four areas (head.
middle part a. middle part b. end). wxhich w-ere counted separately.
Sianificance w-as exaluated using the unpaired t-test (P <0.01).
Inhibition experiments were performed w-ith nerve explants
prexiously injected with 10 tl of IgY solution (5 gia purified anti-
bodies ml- ). Antibodies w-ere present during the whole experiment
(5 jig ml' in the inner and 2.5 jgc ml-' in the outer chambers).
Purification of C6-MPA
C6 plasma membranes were prepared as described by rAmberger et
al (1994) w-ith some modifications. C6 cells wxere growxn in roller
bottles )Costar. 2550 ml). scraped off at confluency and frozen at
- 70-C. Afterthawxing the cell suspension >-as homogenized and a
crude plasma membrane fraction w as obtained by sucrose density
centrifugation (Amberger et al. 1997). The enrichement of C6
plasma membranes w-as determined by measurinn the 5'-nucleoti-
dase actixity. a marker enzvrme for plasma membranes (Ames.
1966). To measure the metalloproteolytic activity of the purified
material the degradation of cbz-phe-ala-phe-tNr-amide >-as
analvsed accordinc to the protocol of Amberger et al (1994). To
remoxve associated membrane proteins the plasma membrane frac-
tions w-ere diluted in MES buffer containing 1 Im marnesium chlo-
ride. shaken for 1 h at 4'C and centrifuged (20000g. 1 h). To
solubilize integral membrane proteins the pellet was resuspended
in I ml of 20 mm MES buffer. pH 6.0. containing 150 mnm sodium
chloride and 1% Triton-X 100. The final pellet >-as resuspended in
MES buffer containing 1 mmi PMSF. 10 jim pepstatin A and 104mi
leupeptin and analysed for protein concentration and peptide
derradation actixvitv.
Plasma membrane Triton X-100 extract >-as applied to a cation
exchange column ()Mono-S) (Pharmacia). equilibrated w-ith 20 mm
MIES buffer. pH 5.0. containing 100 mxi sodium chloride. 100 LiM
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Table 1 Purificaton protocol
- E P ion
(mg) actlft fact'
Hofmogenate 500 10 1
Plasma membranes 110 5 2
Salt wash 88 4 2.5
Triton X-100 extract 70 1.5 7
Mono-S chroktoxgraphy 64 1.4 8
Mono-C chromatography 20 1 11
Size exdusion 9 0.9 12
chromatography
Mono-C chromataphy 3 0.3 36
-Amountdof;g ofprotein needed to degrade 50fmnolcbz-pha-e25-J
tyr-amide i 1 h in te peptide degradaton assay. bMlnimal purification fador,
not tlakng into account loss of enzyme acity.
cobalt chloride and 0.5% CHAPS. The proteins were eluted from
the column with a sodium chloride gradient of 0.1 M to 2 M. A
Mono-Q column was equilibrated with 20 mmi MES buffer, pH 7.5.
containing 100 mM sodium chloride, 100gm cobalt chloride and
0.5% CHAPS. The flow through of the Mono S column, dialysed
against 20 mm MES buffer, pH 7.5 overnight, was applied to the
Mono Q column and proteins were eluted with 20 ml ofa gradient
from 0% to 100% of 20 mM MES buffer, pH 7.5, containing 2 M
sodium chloride, 100gM cobalt chloride and 0.5% CHAPS at a
flow rate of0.5 ml min-'. Pooled fractions containing C6 metallo-
proteolytic activity (C6-MPA), asestimatedbythepeptidedegrada-
tion assay, were dialysed against 20 M MES buffer, pH 6.0.
overnight, and applied to a Superdex 75 column (Pharmacia),
previously equilibrated with 20 M MES buffer with 100 iM
sodium chloride and0.5% CHAPS, pH 6.0. The separation was run
at a flow rate of0.5 ml min-' and fractions of0.5 ml were collected
and tested for enzyme activity. In the last purification step, the
pooled fractions from size exclusion chromatography were sepa-
rated again on Mono-Q FPLC underthe same conditions.
Treatmen of bN1-220 with C6MPA
bNI-220 (bovine) was coated on four-well culture dishes and incu-
bated for 30 min with C6-MPA-enriched fractions (10jig ml-') at
37°C in the presence or absence of EDTA (I mm). Dishes were
washed twice with Ca2+-, Mg2+-free Hanks' balanced salt solution
and used immediately for the spreading assay by adding 10 000
3T3 fibroblasts cm-2. Cells were incubated for 1 h at 37°C, fixed
and evaluated as described above.
Raising of antibodies
Two brown hens, 22 weeks old, were used for immunization
according to the protocol ofGassmann et al (1990). Mono-Q frac-
tion (1 ml) (last purification step) enriched in C6-MPA (0.3 mg
protein ml-') was emulsified with 1 ml ofcomplete Freund's adju-
vant (Gibco Laboratories, New York, USA). The suspension was
injected into the pectoral muscle at four different sites. The first
boost (using complete Freund's adjuvant) was carried out after
200-
116-
45- I
32-
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Figre 1 SDS-PAGE (7.5%) analyss of proteins at successive stages of
the purificabon. Lanes contain the folowg samples. Lane a, C6 cell
homogenate; Lane b, Triton X-100 extract; lane c, Mono-C, nactive fracon;
Lane d, Mono-a, adve fraction; lane e, size exclson, active fraction; lane f,
second Mono-)Q, active fraction. Arrows inicate molecular weight range area
where proteins are enriched
20 days, the second after 32 days. T'he eggs were collected daily,
labelled and stored at 40C until use.
IgY was purified from individual eggs with the EGGstract IgY
purification system from Promega (Madison, WI, USA). The yolk
was carefully separated from the egg white, and yolk lipids were
precipitated IgY was precipitated from the filtered supenatant
while stirring at room temperature and stored in PBS supple-
mented with 0.01% sodium azide in concentrations of 1 mg ml-l at
4°C. The same procedure was performed with preimmune yolk to
obtain control antibodies.
Gel ek s and immunobloting
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) was performed on 5% and 7.5% polyacrylamide gels
according to Laemmli (1970). Gels were stained with silvernitrate
for protein detection. For immunoblotting fractions of anion and
size exclusion columns were separated on 7.5% SDS-PAGE and
transferred to a PVDF membrane. The membrane was blocked
with 3% gelafine hydrolysate in PBS and incubated with IgY anti-
bodies (5 jg ml-') in Tris-buffered saline (TBS, 10 mm Tris-HCI,
pH 7.5, 0.1 M sodium chloride). The secondary antibody
(Promega), coupled to alkaline phosphatase, was used in dilution
1:5000. The bound alkaline phosphatase was localized using BCIP
(5-bromo4-chloro-3-indolylphosphate p-toluidine) and NBT
(nitroblue tetrazolium chloride) as substrates.
RESULTS
Partial purfication of a membrane-bound
metaloprotease from rat C6 glioma cells
Crude cell homogenate of C6 glioma cells was fractionated by
sucrose density centrifugation, resulting in a plasma membrane, a
nuclear and a mitochondrial fraction. The enrichment of plasma
membranes was assessed by measuring the 5' nucleotidase
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Figure 2 Cell spreading of 3T3 fibroblasts and C6 glioma cells on the highly punfied neunte growth inhibitor protein bNI-220 and on control substrate A total of 10 000 3T3 fibroblasts (A. B. E. F) or 10 000 C6 glioma cells (C. D) were plated on wells coated with bNI-220 (B. D-F) or on control wells (A, C) and
incubated for 1 h. E. F Coated wells were preincubated for 30 min with C6-MPA in the absence (E) or presence (F) of EDTA. Bar = 20 um
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Figure 3 The spreading ability of 3T3 fibroblasts on culture dishes coated
with bNI-220 (0.5 jg cm-2) was determined by counting spread cells against
all plated cels at different time points. The substrate bNI-220 was
preincubated with C6-MPA (1 igm a"m) in te presence and absence of EDTA
(1 mm). Values shown are means of three expermnent ± s.e.m. P < 0.001.
7, CNS myelin; *, bNI-220; , bNI-220 + C6-MPA; in, bNI-220 + C6-MPA +
EDTA; h, bNI-220 + inactive fracbon; t, control + C6-MPA + EDTA
activity. Compared with the homogenate (0.09 units mg-') the
plasma membranes showed a 3.3-fold enrichment (0.3 units mg-')
in specific 5'-nucleotidase activity, whereas the nuclear and the
mitochondrial fractions showed much lower activity (0.05 units
mg-'). Testing these plasma membrane fractions for C6-MPA
activity in the peptide degradation assay. we found a twofold
enrichment compared with the cell homogenate.
To determine the type ofmembrane association ofC6-MPA. C6
plasma membranes were treated with 1 M magnesium chlonrde.
This procedure solubilized 25% of the total amount of membrane
proteins. but did not solubilize the C6-MPA activity, suggesting
that this enzyme is an integral membrane protein. To solubilize
C6-MPA. C6 plasma membranes were treated with several deter-
gents at various concentrations and proteolytic activity was deter-
mined in the peptide degradation assay. C6-MPA activity was most
efficiently (90%) solubilized with 1% Triton X-100. Solubilized
plasma membrane proteins were applied on a cation exchange
FPLC column (Mono-S). The majority ofthe cbz-phe-ala-phe-tyr-
amide (FAFY) degrading activity was found in the flow through
fraction. representing 71% ofthe applied proteins. Twenty per cent
of the proteins were eluted with 200-350 mm sodium chloride but
did not show cbz-FAFY-amide degrading activity. The flow
through fractions were pooled and applied to a Mono Q anion
exchange column. Cbz-FAFY-amide degrading C6-MPA was
eluted in a single peak with 400 mm sodium chloride. Subsequent
size exclusion chromatography on a Superdex 75 column.
followed by a second run on the anion exchange column, resulted
in a further enrichment of peptide-degrading activity: 0.3 pg
protein of the final peak fraction degraded 50 fmol peptide per
hour, demonstrating a 36-fold enrichment compared with the crude
C6 cell homogenate. Table 1 summarizes the efficiency of each
purification step. Attempts to further purify the enzyme using
other columns. including affinity chromatography. were unsuc-
cessful because of a strong decrease in metalloproteolytic activity
during further purification procedures. SDS-PAGE analysis ofC6-
MPA-containing fractions at successive steps of the isolation is
shown in Figure 1. In the different purification steps an enrichment
of bands in the higher molecular weight range (Mr 65-180 kDa)
was seen.
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Figure 4 Plasma membrane proteins from C6 glioma cells degrade less
cbz-phe-ala-phe-'l5tyr-amide in the presence of antbodies against C6-MPA
pasma membrane proteins (10 jg) were preincubated with a blocker cocktail
containing 10 m leupeptin, 10 jIu pepstatin A and 1 mu PMSF (Lane d)
and with eiter specific irnune-lgY (5 9g m[ ') (lane c) or preimmune-IgY
(lane b) for 15 min folowed by a 1 h iubation with 100 fmnol cbz-phe-ala-
phe{['2l]tyr-amide at 37°C. Lane a shows the tetrapepbde without plasma
membranes. The degradation products were separated by thin-ayer
chromatography and quantfied
The peptide degrading activity described in all these steps has
always been tested for its sensitivity to specific metalloprotease
blockers. The C6-MPA is blocked by 10 jM o-phenanthroline. a
chelating agent that inhibits metalloproteases. and by 10 gM
phoshoramidone. whereas 300 jM thiorphan had no effect. This
result is in agreement with the blocking effects seen on the C6
enzyme and on C6 cell spreading on a myelin protein substrate
(Paganetti et al, 1988; Amberger et al. 1994). The enriched metal-
loproteolytic activity obtained by this procedure was used for the
experiments described below.
C6-MPA inactfvates neurite growth inhibitors present in
CNS myelin
CNS myelin and the neurite growth inhibitory protein bNI-220
were purified from bovine spinal cords and were used as substrates
for cell spreading of 3T3 fibroblasts and C6 glioma cells. 3T3
fibroblasts attached and spread on control substrate (Figure 2A).
whereas cell spreading was completely inhibited on the inhibitory
substrates (Figure 2B). C6 glioma cells attached and spread
equally well on control dishes (Figure 2C) and on culture dishes
coated with bNI-220 (Figure 2D). Preincubation of bNI-220-
coated culture dishes with C6-MPA-enriched fractions for 30 min
at 37°C changed the substrate properties: 3T3 fibroblasts attached
rapidly and spreading was advanced after I h (Figure 2E).
Pretreatment ofbNI-220 with C6-MPA in the presence of EDTA.
a chelating agent that inhibits metalloproteases, retained the
inhibitory effect of bNI-220 and 3T3 fibroblast spreading was
inhibited (Figure 2F). Quantitative analysis of the inactivation of
bNI-220 by C6-MPA is shown in Figure 3. Coating of0.5 jg bNl-
220 cm-2 inhibited cell spreading of about 80% 3T3 fibroblasts
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during a 90-min incubation. The same result was obtained by
coating 15 gg of bovine CNS myelin extract (74% inhibited 3T3
fibroblasts). Pretreatment with C6-MPA (1 jg cm-2) neutralized
the inhibitory substrate effect of bNI-220 for 3T3 fibroblasts as
seen by a massive reduction in inhibited 3T3 cells (10% inhibited
cells: significance. P < 0.001). This inactivation of bNI-220 by
C6-MPA was strongly impaired by the presence ofEDTA (1 mM).
EDTA alone showed no effect on the inhibitory activity of bNI-
220. Pretreatment of bNI-220 with an inactive fraction (flow
through ofsecond Mono Q) did not reduce the inhibitory substrate
properties: 78% of the fibroblasts were inhibited after 90 min.
Using control substrate in the presence ofC6-MPA and EDTA. no
influence in the spreading ability of3T3 fibroblasts compared with
control substrate alone was observed (24% cells inhibited). These
results show that the inhibitory protein bNI-220. present in CNS
myelin. is inactivated by C6-MPA. The sensitivity ofthe C6-MPA
to EDTA confirms the metalloproteolytic nature ofthis enzyme.
Polyclonal antibodies against C6-MPA
In an attempt to obtain further tools to purify and study the C6-
MPA we immunized two hens with a fraction enriched in C6-MPA
(Mono Q. last punrfication step. Table 1). The antibodies (IgY)
were purified from the egg yolk. Control antibodies were obtained
from preimmune yolk ofthe same hens.
To assay for the presence of antibodies directed against C6-
MPA. the effect ofIgYs was first tested in the peptide degradation
and C6 cell spreading assays. As shown in Figure 4. a significant
reduction in proteolytic degradation ofthe tetrapeptide cbz-FAFY-
amide occurred. Quantification showed a reduction of up to 40(Y7
in degraded tetrapeptide (56 fmol of 100 fmol) in the presence of
the specific antibodies compared with the amount of degraded
peptide without antibodies (95 fmol of 100 fmol). The presence of
control (preimmune) IgY did not reduce the proteolytic activity
(Figure 4).
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Figure 6 Time course of C6 gi*na cell migration on poly-L-lysine and CNS
myelin in the presence of the antbodies. C6 cels migrate on poin
equally well in the presence and absence of immune IgY (5 gg ml-'). In
contrast, cell migrabon was inhibited on CNS myelin in the presence of
immune IgY, but not in the presence of control IgY. The values represent the
mean of three slides and three indepernent experiments s.e.m. -P < 0.01.
=, Control; e, contro + IgY; O, myelin; L1, myelin + IgY; , myelin +
preimnmune IgY
For the cell spreading assay. C6 glioma cells were plated on
CNS myelin and on control substrate in the presence of immune-
IgYs or control IgYs (Figure 5). The antibodies did not affect C6
cell spreading on control substrate (Figure SA). but spreading of
C6 glioma cells on CNS myelin extract was reduced by 90% in the
presence ofimmune-IgYs (Figure SB). Control IgYs did not show
any effect on cell spreading on each substrate (Figure 5C).
Antibody effects on C6 cell migration
The migration ability ofC6 gliomacells in the presence orabsence
of antibodies was tested using slides that were coated either with
CNS myelin extract or with poly-L-lysineIBSA as control
substrate. Cells were plated into narrow bore cylinders that were
Figure 5 Effect of IgYs on C6 glioma cell spreading. A total of 10 000 C6 cels were plated on CNSmnyelin-coated dishes (B, C) and control dies (A) in the
presence of 3 pg ml-' immune IgY (A, B) or preimmune IgY (C). The dishes were incubated for 1 h at 3TC. Bar = 50gm
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TabIe 2 C6 glioma cell invasion
Total number of
Heed Mid a Mid b End C6cells pernerve
Control +++ ++ + (+) n = 482+ 49
Contro-IgY +++ ++ + (+) + n =426+54
Immune-IgY ++ + (+) (+) - n=234_50
(+), -10 cels; +, -50 cells; ++, -100 cells; +, 100-150 cells. Analysis of C6
cells invading optic nerve explant in vitro. Infiltrated cells were counted in
different parts of the explants ('had, 'mid-nerve a', 'mkierve b', 'end').
Nerves (4-5 mmn) were taken from 10- to 12-week-old rats and piaced under
a Teflon ring with silicon grease. Three compartment communicatng only by
the explants were obtained in this way. C6 cells were stained with the
fluorescent dyes Di-I and Hoechst and 200 000 C6 cels were plated into te
middle chanber and incubated for 14 days. Frozen sectons (15 im) were
serially cut on a cryostat Labeled infiltrated cells were counted under a
fluorescence microscope. The values represent the means of three
independent experiments performed in duplicate ± s.e.m. 'P< 0.001.
removed when all cells had attached (2 h). Areas covered by
migrating cells were measured at 2 h. 6 h. 12 h and 24 h. The 2-h
values were defined as base line levels. which were subtracted
from later time points. On the adhesive poly-L-lysineIBSA-control
substrate. C6 cells showed less migratory ability (2.2 mm2) than on
CNS myelin (3.1 mm') (Figure 6). The presence ofcontrol IgY did
not change the migration capacity on both substrates over 24 h. In
contrast. migration ofC6 glioma cells on CNS myelin was signifi-
cantly reduced in the presence of immune IgY (1.7mm2. 45%
reduction, P < 0.01). whereas on control substrate there was no
effect by the antibodies.
Optic nerve invasion in the presence of IgY antibodies
To study glioblastoma cell infiltration into CNS tissue in the pres-
ence or absence of antibodies, C6 cells were added to optic nerve
200-
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explants in a special chamber culture system as described (Schwab
and Thoenen. 1985: Paganetti et al. 1988). After 14 days in vitro.
the optic nerves were serially sectioned and the cells in the
different parts ofthe explants were counted underthe fluorescence
microscope (Table 2).
The cell numbers found in the head of the explants. close to
where C6 cells were originally placed. were the same between
explants without antibodies and explants in the presence ofcontrol
antibodies. whereas they were reduced in the presence of immune
IgYs. A clear reduction was also seen in the other parts of the
explants in the presence of immune IgYs. The total number of
infiltrating cells in the explants cultivated in the presence of
immune IgYs was about halfofthat in explants without antibodies
(Table 2).
Immunoblots
Figure 7 shows the protein and immunoblot patterns of SDS-
PAGE of proteins from different purification steps. Immunoblots
of the C6-MPA-enriched preparation after the anion exchange
chromatography with the specific immune antibodies showed five
major bands. Two of the bands (approximately 220 and 240 kDa)
are also seen in the inactive fractions and with the preimmune anti-
bodies (Figure 7. lane b and lane e). A broad band in the molec-
ular weight range of 105-120 kDa is recognized by the immune
antibodies but only partially by the preimmune antibodies (Figure
7. lane e). Two thinner bands appear in the molecular weight range
of Mr 75-80kDa. which were recognized specifically by the
immune IgY.
A molecular weight range of66 to 96 kD has been estimated for
C6-MPA in earlier studies using HPLC (Ambergeret al. 1994). The
present results show that antibodies raised against aprotein fraction
enriched in metalloproteolytic activity bind to a limited number of
membrane proteins from C6 glioma cells in the same molecular
weight range. Immunostaining of living cells resulted in a strong
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Figure 7 Protein- and immunoblot-pattem of different purification steps. Lanes a-d, SDS-PAGE, silver stained. Lane a, C6 cell homogenate; lane b, first step
Mono 0, flowthrough, inactve fracbon; lane c, Mono-0, active fracbon; Lane d, size exdusion. Lanesa'-d', correspondi immunoblot with immune-IgY; lane e,
Mono-Q, active fraction, control-IgY
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staining ofC6 glioma cells, whereas PC-12 cells (a tumourderived.
neuronal cell line). astrocytes and 3T3 fibroblasts did not show
detectable staining (data not shown), indicating that the recognized
antigens are exposed to the extracellular environment.
DISCUSSION
In the present study we report the partial purification of a metallo-
proteolytic activity found in the plasma membrane of C6 glioma
cells (C6-MPA) and generation ofIgY antibodies against fractions
enriched in this activity. Further, we show evidence for the
involveement of C6-MPA in glioma cell spreading and migration
on CNS myelin and infiltration of CNS tissue explants. The
neurite growth inhibitory protein bNI-220. which also inhibits
fibroblast and astrocyte cell spreading and migration. was inacti-
vated by C6-MPA. Antibodies raised in chicken by immunization
with fractions ennrched in C6-MPA were able to inhibit C6 glioma
cell spreading and migration on myelin. as well as invasion into
optic nerve explants.
In vivo. malignant astrocytomas spread mainly through the
white matter of brain tissue and for their dissemination follow
white matter fibre tracts (Russel and Rubinstein. 1989). Similar
observations have been made with the rat C6 glioma line. which
shows rapid infiltration ofbrain tissue in vivo and migration pref-
erentially along myehnated fibre tracts. The specific molecular
interactions that mediate glioma cell migration along CNS fibre
tracts are largely unknown (Giese et al. 1994). One important
component ofthe brain white matter is myelin. containing specific
membrane proteins that inhibit axon regeneration. neurite
outgrowth and cell spreading ofastrocytes and fibroblasts (Caromn
et al. 1988: Rubin et al. 1995).
lTe fact that the main route of malignant brain tumour infiltra-
tion is along white matter fibre tracts suggests that gliomas use a
specific mechanism to overcome the effect of these myelin-
associated inhibitory proteins. O-Phenanthroline. a chelator that
inhibits metalloproteases. and the derived tetrapeptide cbz-FAFY-
amide inhibit spreading and migration ofC6 cells as well as human
glioblastoma cells on CNS myelin in vitro (Paganetti et al. 1988;
Amberger et al. 1994. 1997). This shows that a mietalloproteolytic
activity, blocked by o-phenanthroline or the tetrapeptide. is neces-
sary in a mechanism involved specifically in glioma cell spreading
on CNS myelin. In the present study we have shown that a C6
glioma plasma membrane fraction enriched in metalloproteolytic
activity inactivates the inhibitory substrate properties of CNS
myelin as well as highly purified bNI-220 (bovine homologue of
NI-250) for cell spreading. This inactivation was blocked in the
presence ofEDTA. confirming the action ofa metalloprotease.
Antibodies raised in chicken against plasma membrane frac-
tions enriched in metalloproteolytic activity reduced the degrading
activity of C6-MPA. suggesting that these polyclonal antibodies
contain antibodies against this metalloprotease (although an indi-
rect masking effect cannot be excluded at present). That a certain
amount ofthe tetrapetide was still degraded might be explained by
the possibility that the antibodies do not bind directly to the active
centre of the protease but to a region close by. Cell spreading and
migration on myelin and invasion of C6 glioma cells into optic
nerve explants were significantly reduced in the presence of the
antibodies. indicating the involvement of proteins recognized by
the antibodies, e.g. the C6-MPA. SDS-PAGE and immunoblots
point to candidate bands for C6-MPA in the molecular weight
range of 75-SO kDa. This is in line with earlier estimates of the
molecular weight range ofthis membrane-bound metalloendopro-
tease between 66 and 96 kDa (Amberger et al. 1994).
Tumour cells produce several classes of proteases. such as
matnix metalloproteases (MMPs). serine proteases. cysteine
proteases and aspartyl proteases. that have been involved in migra-
tion and invasion of different tumour types (Ennis and Matrisian.
1994; Romanic and Madri. 1994). Recently. a new class of
membrane-bound matrix metalloproteases (MT-MMPs) has been
identified (Sato et al. 1994). The expression of MT-MMP-I is
correlated with gelatinase A activation, and MT-MMP-1 mRNA
was found to be significantly elevated in malignant astrocytomas
(Yamamoto et al. 1996).
Our results suggest that migration of glioblastoma cells along
white matter fibre tracts of the CNS is not simply the result of
structural factors, but involves the inactivation of specific
inhibitory substrate properties ofCNS myelin by acrucial involve-
ment of a membrane-bound metalloprotease. The subsequent
molecular interactions ofthe migrating glioblastomas with myelin.
white matter astrocytes or axons remain unknown. The impair-
ment of cell migration by inactivation of the metalloprotease
shown here in vitro points to interesting future applications of
metalloprotease blockers for the prevention ofglioblastoma spread
in vivo.
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